Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Buy” from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $28.83.

A number of research analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Finally, JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of KURA. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Kura Oncology by 12.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock worth $874,000 after buying an additional 4,659 shares during the period. SG Americas Securities LLC acquired a new stake in Kura Oncology in the 1st quarter worth about $110,000. Susquehanna Fundamental Investments LLC acquired a new stake in Kura Oncology in the 1st quarter worth about $507,000. ProShare Advisors LLC raised its stake in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after purchasing an additional 1,588 shares in the last quarter. Finally, Entropy Technologies LP acquired a new stake in Kura Oncology in the 1st quarter worth about $218,000.

Kura Oncology Stock Down 7.1 %

Kura Oncology stock opened at $16.49 on Friday. The company has a market cap of $1.28 billion, a P/E ratio of -6.99 and a beta of 0.86. Kura Oncology has a 1-year low of $8.80 and a 1-year high of $24.17. The company has a fifty day simple moving average of $18.57 and a 200 day simple moving average of $19.95. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.